Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.
In this study we investigated the effect of rebamipide enema in patients with steroid-resistant and/or dependent ulcerative colitis. Rebamipide enemas were administered twice daily for a 12-week period; this treatment was further continued longer in patients who requested this. Disease activity index as reflecting the clinical condition and endoscopic index with histological grading were determined before and after the treatment period. Nine of 11 (81.8%) patients on 12-week treatment with rebamipide approved and were classified as colitis in remission. Moreover, seven of 11 patients requested long-term medication, the longest medication term being 80 weeks. These results medicated that rebamipide enemas may be effective in patients with steroid-resistant and/or dependent ulcerative colitis.
Miyata
Mitsuki
M
Department of Gastroenterology, Aichi Medical University School of Medicine, Aichi-Gun, Aichi 480-1195, Japan. mmiyata@ aichi-med-u.ac.jp
Kasugai
Kunio
K
Ishikawa
Tetsuya
T
Kakumu
Shinichi
S
Onishi
Masafumi
M
Mori
Takeshi
T
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000328:Adult; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology*; D004351:Drug Resistance; D004733:Enema; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D015363:Quinolones / Q000008:administration & dosage* / Q000627:therapeutic use*; D012720:Severity of Illness Index
D000305:Adrenal Cortex Hormones; D000897:Anti-Ulcer Agents; D015363:Quinolones; C052785:rebamipide; D000409:Alanine